Acute Esophageal Damage in Patients with Inoperable Non-small Cell Lung Cancer Treated with Concurrent and Sequential Chemoradiotherapy
BACKGROUND: Acute esophageal damage may be a dose-limited factor for application the full planning radiotherapy (RT) dose in patients with inoperable non-small cell lung cancer (NSCLC). A combination of chemotherapy and RT may increase esophageal toxicity, but three-dimensional (3D) conformal RT offers better sparing of the organs at risk.
AIM: The purpose of this study was to show the incidence and degree of acute esophageal damage in lung cancer patients treated with sequential and concurrent chemoradiotherapy.
MATERIALS AND METHODS: The total number was 73 patients, of whom 26 (34.7%) had previously received sequential chemotherapy with a four-cycle followed by RT. In the second concurrent group, 47 (65.3%) patients were received concomitant chemotherapy and RT.
RESULTS: Of the 73 patients included in the study, 43 (57.3%) did not present any grade of esophagitis during the treatment. In the sequential group, 73.1% presented no esophagitis and in the concurrent group, 49%, respectively. Although there were differences between the two groups, none were statistically significant.
CONCLUSIONS: The reason for the good tolerability of the combination of chemotherapy and RT for inoperable NSCLC patients was using 3D conformal RT. Further improvements may be obtained with more sophisticated RT or radioprotective drugs.
Plum Analytics Artifact Widget Block
World Health Organization Statistics. Available from: http://www. who.int/mediacentre/factsheets/fs297/en. [Last accessed on 2017 Dec 21].
Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable NSCLC: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83(6):417-23. https://doi.org/10.1093/jnci/83.6.417 PMid:1847977
Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, et al. Phase III comparison of seguential vs. Concurrent chmoradiation for patients with unresected stage III NSCLC: Initial report of RTOG 9410. Proc ASCO. 2000;19:484a. https://doi.org/10.1016/ s0169-5002(00)80304-9
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6. PMid:7713792
Furuse K, Fukuaka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692-9. https://doi.org/10.1200/ jco.19184.108.40.20692 PMid:10561343
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancers. J Clin Oncol. 2006;24(30):4833-9. https://doi.org/10.1200/jco.2006.07.5937 PMid:17050868
Choi GB, Shin JH, Song HY, Lee YS, Cho YK, Bae JI, et al. Fluoroscopically guided balloon dilation for patients with esophageal stricture after radiation treatment. J Vasc Interv Radiol. 2005;16(12):1705-10. https://doi.org/10.1097/01. rvi.0000179813.93992.9e PMid:16371539
Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with NSCLC treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55(2):337-41. https://doi.org/10.1016/ s0360-3016(02)03937-8 PMid:12527046
Qiao WB, Zhao YH, Zhao YB, Wang RZ. Clinical and dosimetric factors of radiation induced esophageal injury: Radiation induced esophageal toxicity. World J Gastroenterol. 2005;11(11):2626-9. https://doi.org/10.3748/wjg.v11.i17.2626 PMid:15849822
Ahn SJ, Kahn D, Zhou S, Yu X, Hollis D, Shafman TD, et al. Dosimetric and clinical predictors for radiation induced esophageal injury. Int J Radiat Oncol Biol Phys. 2005;61(2):335-47. PMid:15667951
Chapet O, Kong FM, Lee JS, Hayman JA, Haken RK. Normal tissue complication probability modeling for acute esophagitis inpatients treated with conformal radiation therapy for NSCLC. Radiother Oncol. 2005;77(2):176-81. https://doi.org/10.1016/j. radonc.2005.10.001 PMid:16256230
Bradley J, Deasy JO, Benzen S, El-Naqa I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys. 2004;58(4):1106-13. PMid:15001251
O’Rourke N, Roque IF, Bernado NF, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6;CD002140. PMid:20556756
Byhardit RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, et al. Response, toxicity, failure patterns and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemothterapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998;42(3):469-78. https://doi.org/10.1016/ s0360-3016(98)00251-x PMid:9806503
Fairchild A. Side effects of palliative radiation therapy. In: Lutz S, Chow E, Hoskin P, editors. Radiation Oncology in Palliative Cancer Care. West Sussex, UK: Wiley-Blackwell; 2013. p. 43-60. https://doi.org/10.1002/9781118607152.ch5
Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting esophagitis after chemotadiation therapy for NSCLC: An individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87(4):690-6. PMid:24035329
Bradley JD, Paulus R, Komaki R, Masters G, BlumenscheinG, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187- 99. https://doi.org/10.1016/s1470-2045(14)71207-0 PMid:25601342
Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J, et al. Acute esophageal toxicity in NSCLC patients after high dose conformal radiotherapy. Radiother Oncol. 2005;75(2):157-64. https://doi.org/10.1016/j. radonc.2005.03.021 PMid:15890421
Liao ZX, Komaki RR, Thames HD Jr., Liu HH, Tucker SL, Mohan R, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced NSCLC receiving concomitant chemoradiotherapy. Int J Radiati Oncol Biol Phys. 2010;76(3):775-81. https://doi.org/10.1016/j.ijrobp.2009.02.0 PMid:19515503
Wei X, Liu HH, Tucker S, Liao Z, Hu C, Mohan R, et al. Risk factors for acute esophagitis in NSCLC patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):100-7. https://doi.org/10.1016/j.ijrobp.2006.04.022 PMid:16839700
Wemer-Wask M, Scott C, Paulus R, Curran WJ Jr, Byhardt R. Correlation between acute esophagitis and late pneumonitis in patients with locally advanced NSCLC receiving concurrent thoracic radiotherapy; a multivariate analysis of Radiation Therapy Oncology Group database. ASCO Annu Meet. 2002;21:1192-299.
Takeda K, Nemoto K, Satio H, Ogawa Y, Takai Y, Yamada S. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(3):626-9. PMid:15936536
Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Guerra JL, et al. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for NSCLC. Int J Radiat Oncol Biol Phys. 2012;84(4):1010-6. https://doi.org/10.1016/j.ijrobp.2012.01.071 PMid:22920974
Marks LB, Yorke ED, Jackson A, Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76 Suppl 3:S10-9. PMid:20171502
Copyright (c) 2020 Simonida Crvenkova, M. Popova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.